SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 µM and 2.97 µM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD)-related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD[1].
Molecular Weight:
545.45
CAS Number:
[3052985-32-4]
Formula:
C27H21BrN4O2S
Target:
JNK,Pyruvate Kinase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
